$0.42
+8.92%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.40
From 52W high−66.55%
Volume867500.00
Market cap$55.70M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.40
From 52W high
−66.55%
Volume
867500.00
Market cap
$55.70M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
27.0
MomentumView details →
1D Return
+8.92%
YTD Return
−53.16%
SummaryUpdated Jun 1, 2026
Oncolytics Biotech Inc. (NASDAQ:ONCY) is a Canadian development-stage biopharmaceutical company founded in 1998 and headquartered in Calgary, Alberta. The company went public in 2001 and has spent over two decades developing its lead therapeutic candidate, pelareorep, an oncolytic virus-based immunotherapy for cancer treatment. As a clinical-stage biotechnology company, Oncolytics has no commercial products and generates no revenue, instead focusing entirely on advancing pelareorep through various clinical trials targeting multiple cancer types including breast, pancreatic, and anal cancers.
Similar companies
Latest newsMore news →
ONCOLYTICS BIOTECH INC announced new translational data from an ongoing anal cancer study showing pelareorep increased HPV-16-specific T-cell clones and tumor-infiltrating lymphocyte clones in patients.10h agoONCOLYTICS BIOTECH INC reported GOBLET study data showing that all responding anal cancer patients survived for longer than one year.8d agoONCOLYTICS BIOTECH INC announced that it is presenting a trial-in-progress abstract and e-poster on the REO 033 study at the ESMO Congress 2026.15d ago